Senate To Review Dental Industry Red Tape
28th Dec 17
ADIA has been invited to provide advice to the Senate’s select committee on red tape which is reviewing how the health sector is disadvantaged by regulations that are burdensome, complex, redundant or duplicated across jurisdictions..
Key Issues For The Dental Industry —
As part of its inquiry into the effect of red tape on the economy and community, the Senate Select Committee on Red Tape is examining examine the effect of red tape on health services. The Australian Dental Industry Association (ADIA), as the peak business organisation representing dental product manufacturers and suppliers, has been invited to tender advice to this committee.
With the advice and guidance of member businesses, ADIA will assist the Senate committee in identifying specific areas of red tape that are particularly burdensome, complex, redundant or duplicated across jurisdictions. Naturally, there will be a focus on dental product regulation and the work of the Therapeutic Goods Administration (TGA); however, ADIA’s focus is likely to be broader.
ADIA member businesses are encouraged to get involved in this work with the lead to be taken by members serving on the following national committees:
One of key issues to be considered by the ADIA-TCPC Committee and the ADIA-PRPC Committee will be recent efforts of the Australian Government to reduce red tape and the degree which these have been effective. Issues to be addressed include the effects on compliance costs (in hours and money), economic output, employment and government revenue.
ADIA's policy objective will be to remove the regulatory barriers that frustrate the ability of member businesses to grow, create jobs and operate sustainably. In achieving this the environment will be created where the dental industry can empower oral health professionals to advance the health and well-being of all Australians.
Businesses across the dental industry are being encouraged to advice the ADIA policy team of the issues facing their businesses by sending an email to email@example.com not later than 15 January 2018. The unusually short period to for members tender advice to ADIA is due to the dates set by the Senate for industry consultation.
Member Engagement —
ADIA's submission is being prepared by the policy team within the national office who receive support from employees of member businesses serving on the ADIA-TCPC Trade & Commercial Policy Committee and the ADIA-PRPC Product Regulation Policy Committee.
Further Information —
For further information on the preparation of the dental industry's submission to this enquiry an email to firstname.lastname@example.org or telephone 1300 943 094. To keep up to date follow ADIA on Facebook at www.facebook.com/dental.industry or subscribe to the Twitter feed @AusDental.
Currency Of Information & Disclaimer —
This update was issued on 28 December 2017 and please note that changes in circumstances after the publication of material or information may impact upon its accuracy and also change regulatory compliance obligations. The statements, regulatory and technical information contained herein are believed to be accurate and are provided for information purposes only. Readers are responsible for assessing its relevance and verifying the accuracy of the content. To the fullest extent permitted by law, ADIA will not be liable for any loss, damage, cost or expense incurred in relation to or arising as a result of relying on the information presented here.
This information is available for your use under a Creative Commons Attribution 3.0 Australia licence, with the exception of the ADIA logo, other images and where otherwise stated.
|A —.. A D I A . .S T R A T G E G I C . .A L L I A N C E S
24th Apr 18
Australia’s leading manufacturers of dental products showcased their reputation in the Australian pavilion at the IDEM Singapore dental show held over 13-15 April 2018.
8th May 18
Local manufacturers and importers of dental laboratory products are being urged to step-up and meet their legal obligations by reporting their activities to the Therapeutic Goods Administration (TGA).